<DOC>
	<DOCNO>NCT03036592</DOCNO>
	<brief_summary>The purpose investigation assess role melatonin receptor 1B ( MTNR1B ) single nucleotide polymorphism ( SNP ) *food time interaction glucose control deleterious effect vulnerable population regular exposure concurrent high melatonin food intake late night eater ( dinner within 2.5 h usual bed time ) . With result study , expect advance understanding role endogenous melatonin glucose metabolism late night eater carrier MTNR1B risk allele , potential implication guideline mitigate risk type 2 diabetes late night eater carrier MTNR1B risk allele .</brief_summary>
	<brief_title>MTNR1B SNP*Food Timing Interaction Glucose Control</brief_title>
	<detailed_description>Late-night dinner eat associate increased risk type-2-diabetes . The underlie mechanism unclear . One explanatory hypothesis concurrence elevate circulate melatonin high glucose concentration ( characterize late-eating ) lead impaired glucose-tolerance . However , date , study test influence physiological melatonin concentration glucose tolerance . The discovery melatonin receptor MTNR1B diabetes risk gene provide evidence role physiological level melatonin glucose control . The aim current study test hypothesis concurrence meal timing elevate endogenous melatonin concentration result impair glucose control effect strong homozygous MTNR1B risk carrier non-carriers . To test glucose tolerance use identical mixed meal two glucose oral tolerance test ( OGTT ) condition : ) delay OGTT Late Eating ( LE ) : starting1 hour usual bed time , b ) advance OGTT Early Eating ( EE ) : start 4 hour habitual bed time , randomize , cross-over study design . These finding could support clinical application screen SNP possibility implement tailor cost-effective behavioral intervention prevent type 2 diabetes vulnerable population . These goal achieve specific approach : â€¢ Interventional ( randomize , cross-over controlled trial ) ( Aim 1 ) : To study potential interaction meal timing ( dinner ) genetic variant MTNR1B glucose tolerance obese woman ( n=1000 ) .</detailed_description>
	<criteria>I Body Mass Index : &gt; 18.5 &lt; 40 kg/m2 Age : 18 65 year age Caucasian Day worker Receiving treatment thermogenic , lipogenic , drug Diabetes mellitus , chronic renal failure , hepatic disease , cancer diagnosis Bulimia diagnosis , prone binge eat Undergoing treatment Type 2 diabetes mellitus ( high blood sugar ) medication Metformin nonMetformin oral antidiabetic drug sulfonylurea , meglitinides , glitazones Undergoing treatment Corticosteroids/steroids , Growth hormone , Anticoagulant medicine , blood thinner , Beta blocker hypertension , Medications sleep , Fluvoxamine , Opioids Amphetamines , Tranquilizers , nonsteroidal antiinflammatory drug . Pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Glucose tolerance test , MTNR1B , nutrigenomics , food timing</keyword>
</DOC>